Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma

Pediatr Surg Int. 2022 Aug;38(8):1149-1155. doi: 10.1007/s00383-022-05143-w. Epub 2022 Jun 16.


Purpose: To assess the efficacy of transcatheter arterial embolization (TAE) plus propranolol treatment for infantile hepatic hemangioma (IHH).

Methods: A retrospective study of symptomatic IHH and hemodynamic changes in IHH was conducted between 2016 and 2019.

Results: There were five boys and seven girls with diffuse lesions (n = 7) and multifocal lesions (n = 5). Hepatomegaly and abdominal distension (n = 6) were the predominant clinical presentations. Seven patients (58.3%) had multiple cutaneous hemangiomas. Pulmonary arterial hypertension, heart failure (n = 4), and hypothyroidism (n = 4) were observed. A total of 17 TAE procedures were performed in 12 IHH cases, with a technical success rate of 100%. All patients received standard propranolol orally, and one patient was orally administered metacortandracin. Two patients died of heart failure and multiple organ dysfunction caused by an enlarged liver. In addition, one patient was not reexamined after discharge. Of the remaining nine children, the average follow-up time was 10.78 months (range 2-28 months), and they all responded well to TAE combined with oral propranolol.

Conclusion: TAE combined with propranolol is safe and effective for the treatment of IHH, demonstrating low complication rates.

Keywords: Embolization; Infantile hepatic hemangioma; Prognosis; Propranolol.

MeSH terms

  • Child
  • Embolization, Therapeutic* / methods
  • Female
  • Heart Failure* / complications
  • Heart Failure* / drug therapy
  • Hemangioma* / drug therapy
  • Hemangioma, Capillary*
  • Humans
  • Infant
  • Liver Neoplasms* / drug therapy
  • Male
  • Propranolol / therapeutic use
  • Retrospective Studies
  • Treatment Outcome


  • Propranolol